Prevention of rheumatic fever. A statement for health professionals by the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association.
D000572:American Heart Association; D002511:Cephalosporins / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D006801:Humans; D010401:Penicillin G Benzathine / Q000627:therapeutic use; D010404:Penicillin V / Q000627:therapeutic use; D010612:Pharyngitis / Q000188:drug therapy*; D010614:Pharynx / Q000382:microbiology; D012008:Recurrence; D012213:Rheumatic Fever / Q000517:prevention & control*; D013290:Streptococcal Infections / Q000188:drug therapy*; D013297:Streptococcus pyogenes / Q000302:isolation & purification; D013997:Time Factors; D014481:United States
D002511:Cephalosporins; D004917:Erythromycin; D010401:Penicillin G Benzathine; D010404:Penicillin V